Diuresis in Acute Kidney Injury (AKI)

1. KDIGO 2012 Guideline Recommendations

KDIGO Recommendation 3.4.1

"We recommend NOT using diuretics to prevent AKI." (Grade 1B)

KDIGO Recommendation 3.4.2

"We suggest NOT using diuretics to treat AKI, except in the management of volume overload." (Grade 2C)

KDIGO Rationale

• Loop diuretics theoretically protect against AKI by decreasing oxygen consumption in the loop of Henle (by inhibiting Na-K-2Cl cotransporter), thus potentially lessening ischemic injury to the vulnerable outer medullary segments.
• Despite this rationale, clinical evidence does NOT support diuretics for prevention or treatment of AKI. Observational studies (59-70% of AKI patients received diuretics before RRT) confirm widespread use but no benefit.
• Diuretics should NOT be used to convert oliguric to non-oliguric AKI as a therapeutic goal.
• The only accepted indication is management of symptomatic volume/fluid overload.
• Mannitol: Increases urine flow but does NOT confer additional benefit beyond adequate hydration; not recommended routinely.
• Loop diuretics to facilitate RRT discontinuation: No evidence of benefit.

KDIGO Algorithm (Stage-Based Management Framework)

AKI Identified
       |
       v
Assess volume status
       |
    ___|___
   |       |
Volume     Euvolemic or
Depleted   Hypervolemic
   |             |
Fluid       Fluid and Na+
resuscitate  restriction
(isotonic       |
crystalloids)   v
           Symptomatic volume
           overload present?
              |
           YES|  NO
              |   |
              v   --> Monitor, supportive care
    Loop diuretic (furosemide)
    IV bolus or continuous infusion
    *NOT to prevent or reverse AKI*
    *ONLY to manage fluid overload*
              |
              v
    Diuretic-resistant overload?
              |
              v
    Consider RRT/ultrafiltration

2. Harrison's Principles of Internal Medicine (22nd Ed, 2025)

• Hypervolemia in oliguric/anuric AKI can be life-threatening (acute pulmonary edema).
• Fluid and sodium should be restricted; diuretics may be used to increase urinary flow.
• "There is no evidence that increasing urine output itself improves the natural history of AKI, but diuretics may help to avoid the need for dialysis in some cases."

• In severe volume overload: Furosemide bolus 200 mg IV followed by an IV drip of 10-40 mg/h, with or without a thiazide diuretic.
• In decompensated heart failure: Stepped diuretic therapy was found superior to ultrafiltration in preserving renal function.
• Low-dose dopamine: Risks (arrhythmias, bowel ischemia) outweigh benefits; not recommended specifically for AKI.
• Harrison's Principles of Internal Medicine 22E, p. (Supportive Measures for AKI)

3. Brenner and Rector's The Kidney

Loop Diuretics in AKI

• High-dose IV diuretics commonly prescribed for oliguric AKI - helps volume management and minimizes progressive volume overload, BUT:
  • No evidence that diuretic therapy alters the natural history of AKI or improves mortality or dialysis-free survival.
  • In a retrospective analysis, diuretic therapy was associated with increased risk of death and non-recovery - but this risk was restricted to non-responders; in diuretic-responsive patients, outcomes were similar to untreated patients.
  • A prospective RCT of high-dose IV furosemide augmented urine output but did not alter outcome of established AKI.
• Key recommendation: Loop diuretics should be used solely to facilitate management of extracellular volume overload.

Furosemide Stress Test (FST) - Brenner and Rector

• A single dose of furosemide 1.0-1.5 mg/kg (1.0 mg/kg if furosemide-naive; 1.5 mg/kg if prior exposure).
• Measure urine volume over 2 hours.
• Urine output < 200 mL in 2 hours = sensitivity 87.1% and specificity 84.1% for progression to AKIN stage 3.
• This characterizes risk of progressive AKI; helps triage patients who may need RRT.
• Brenner and Rector's The Kidney, p. 1270 (Loop Diuretics)

4. Comprehensive Clinical Nephrology (7th Edition)

Fluid Overload Management Algorithm

1. Minimize all fluid intakes.
2. Optimize systemic and kidney perfusion.
3. Initiate IV bolus loop diuretic - particularly in heart failure or nephrotic syndrome where oral bioavailability is reduced.
4. If response to IV bolus is obtained → switch to continuous infusion (less ototoxic than repeated high-dose boluses).
5. Always give a bolus before starting or increasing a continuous infusion.
6. When fluid overload cannot be managed medically:
   • Positive-pressure ventilation (± intubation)
   • Initiate dialysis

• Morphine IV: 2-4 mg over 3 minutes, repeat at 5-15 min intervals.
• Nitroglycerin IV: Start at 5 μg/min (reduces LV filling pressure via venodilation).
• Natriuretic peptides: Currently NO evidence to support as adjunctive treatment in AKI.
• Comprehensive Clinical Nephrology, 7th Ed, p. 1012 (Fluid Overload in AKI)

5. Campbell Walsh Wein Urology

• Diuretic therapy in AKI with volume overload: commonly used.
• "Diuretic therapy used appropriately neither hinders nor hastens recovery from AKI."
• Response to diuretic therapy is a favorable prognostic sign in AKI.

• Bumetanide and torsemide: Increased potency, better oral bioavailability; torsemide has longer duration of action.
• Ethacrynic acid: Used in sulfonamide allergy; more ototoxic at high doses.

• Add metolazone 2.5-5 mg/day (thiazide-like) to loop diuretics for diuretic-resistant cases.
• Blocks distal sodium reabsorption - can produce impressive diuresis.
• Monitor closely for hypokalemia and metabolic alkalosis.
• If minimal response to loop + thiazide → proceed to dialysis/ultrafiltration.
• Campbell Walsh Wein Urology, p. (Management of AKI)

6. Washington Manual of Medical Therapeutics

Furosemide Stress Test (FST) - Detailed Criteria

• Used when: signs of volume overload + oliguria present.
• Dose: 1.0 mg/kg (furosemide-naive) or 1.5 mg/kg (prior exposure).
• Measure: Urine output over first 2 hours.
• Result: < 200 mL = best combination of sensitivity and specificity; predicts progression to advanced AKI stages.
• Prerequisites: Patient must be euvolemic or hypervolemic (NOT volume-depleted); must NOT be on pressor support.
• "Continuing diuretic therapy if a response is seen has not been shown to hasten recovery but can simplify overall management."
• Washington Manual of Medical Therapeutics, p. 480 (Tubular section - ATN management)

7. Tintinalli's Emergency Medicine

• FST: Administer 1 mg/kg furosemide (naive) or 1.5 mg/kg (prior exposure) in AKI stage ≤2.
• Urine output < 200 mL over 2 hours: Sensitivity 87.1%, specificity 84.1% for AKIN stage 3 progression.
• Mannitol: No role in treatment of AKI.
• Low ("renal")-dose dopamine: Does NOT improve renal recovery or decrease mortality.
• Tintinalli's Emergency Medicine, p. 610

8. Diuretic Phase of AKI (Goldman-Cecil Medicine)

• Retained urea (accumulated during oliguria) drives an osmotic diuresis once tubular function begins recovering.
• Large urine volumes may persist; risk of dehydration and electrolyte abnormalities.
• Monitor sodium, potassium, and volume status closely during this phase.
• Hypercalcemia may occur during the diuretic phase of AKI (e.g., rhabdomyolysis-related AKI) due to remobilization of calcium from soft tissues.
• Goldman-Cecil Medicine, (Solute Diuresis / Polyuria section)

Summary Table

Recent Evidence Update

Oliguria in AKI: When Diuretics Help vs. Harm

The Core Distinction: Volume Status

Why Diuretics Are HARMFUL in Prerenal Oliguria

• Prerenal oliguria = kidneys are making little urine because they are trying to conserve volume
• The tubules are intact and functioning - they are avidly reabsorbing sodium and water (hence FENa < 1%)
• Giving a loop diuretic blocks this compensatory conservation, worsening volume depletion, further reducing renal perfusion, and potentially pushing the patient from prerenal AKI into structural ischemic ATN

Why Diuretics Are Used in Established AKI with Overload

• Tubules are already damaged and NOT conserving sodium
• The oliguria is now mechanical (tubular debris, cast formation, back-leak)
• The patient is accumulating fluid and at risk of pulmonary edema
• Here, a diuretic does not worsen the kidney - it relieves the overload

The Furosemide Stress Test (FST) Caveat

"Patients must be euvolemic or hypervolemic to qualify for this test and should not be on pressor support."

Practical Decision Algorithm

Patient with oliguria in AKI
           |
    Assess volume status
     (JVP, IVC on USS, BP, skin turgor, fluid balance)
           |
    ________|________
   |                 |
VOLUME              VOLUME
DEPLETED            OVERLOADED
(Prerenal)          (Fluid overload)
   |                     |
Fluid                 Diuretics ONLY
resuscitate           to manage overload
(isotonic             NOT to treat AKI
 crystalloids)        NOT to convert
   |                  oliguric → non-oliguric
NEVER give
diuretics here

Bottom Line

• Oliguria per se ≠ contraindication
• Hypovolemic oliguria = contraindication (diuretics will cause harm)
• Hypervolemic oliguria (established AKI with fluid overload) = the only indication, but solely to manage the overload, not to treat the AKI

Diuresis in ATN - Mechanistic Analysis

First: The Full Pathophysiology of Oliguria in ATN

The Theoretical Argument FOR Diuretics in ATN

• Higher tubular flow rate = casts are less concentrated, less likely to aggregate with Tamm-Horsfall protein
• CCN specifically notes: "Conditions that further reduce flow rates, such as volume depletion, can accelerate tubule obstruction" - meaning LOW flow WORSENS cast formation
• Acidic pH and high sodium concentration in the lumen favor uromodulin dimerization and cast formation
• Therefore, anything increasing tubular flow (including diuretics) could theoretically reduce cast formation and obstruction

• Loop diuretics block the Na-K-2Cl cotransporter in the thick ascending limb
• This prevents excess NaCl from signaling at the macula densa
• Therefore blunts the afferent arteriolar constriction that TGF causes
• KDIGO acknowledges this as the theoretical rationale: "Loop diuretics may decrease oxygen consumption in the loop of Henle by inhibiting sodium transport, thus potentially lessening ischemic injury"

Why the Theory Doesn't Translate to Clinical Benefit

1. Cast obstruction is only ONE of four mechanisms. The other three (cell death, back-leak, reduced GFR from vasoconstriction) are completely unaffected by diuresis.
2. Back-leak may actually be the dominant mechanism in severe ATN - CCN notes it can account for up to 50% of GFR reduction in severe cases (such as transplant ATN). No diuretic can fix a broken epithelial barrier.
3. The TGF mechanism is already overwhelmed: In established ATN, ischemic injury to the tubule is the primary driver - the TGF component is a secondary amplifier, not the cause.
4. Diuretics cause further ischemia to the already-vulnerable outer medullary thick ascending limb (the S3 segment and mTAL are the most oxygen-hungry, least blood-supplied segments). Forcing them to work harder by increasing tubular flow paradoxically increases their oxygen demand in a region of borderline perfusion.

The Special Case: Rhabdomyolysis-ATN (Where Fluids ARE the Treatment)

"Early and aggressive volume repletion is mandatory in rhabdomyolysis, who may initially require 10 L of fluid per day. Diuretics may be used if fluid repletion is adequate but unsuccessful in achieving urinary flow rates of 200-300 mL/h."

• Dilute myoglobin casts before they form
• Wash out tubular debris mechanically
• Maintain tubular flow so casts don't consolidate

• Reduces hemoglobin binding to Tamm-Horsfall protein
• Inhibits redox cycling of myoglobin (reduces lipid peroxidation)
• Dissociates already-formed casts

Similarly: Myeloma Cast Nephropathy

• Light chains bind Tamm-Horsfall protein under low tubular flow conditions
• Volume depletion accelerates cast formation
• Treatment: aggressive hydration to increase tubular flow, reduce FLC-THP binding opportunity
• Again - fluid-driven high flow is the mechanism, not the diuretic per se

Summary: Practical Answer

Tubular cast obstruction in ATN
             |
    Is fluid loading adequate?
             |
    _________|_________
   |                   |
   NO                 YES (euvolemic/hypervolemic)
   |                   |
Fluids FIRST     High urine flow achieved?
(restore               |
 tubular flow)    _____|_____
                 |           |
                YES          NO
                 |           |
           Continue      Add diuretic to
           fluids        augment flow
                         (secondary role)
                              |
                    Watch: Are you now worsening
                    medullary ischemia?

• The flushing/diluting concept is real and valid - it's the basis for aggressive fluid therapy in rhabdomyolysis and myeloma cast nephropathy
• But in ischemic ATN, tubular obstruction is only one of four mechanisms - the others (cell death, back-leak) cannot be fixed by flow
• Diuretics do not improve recovery from established ATN because they cannot repair dead cells or broken tight junctions
• Fluids are the primary tool for cast prevention/dilution; diuretics are only added if fluid loading fails to generate adequate urine flow, and only in the absence of further ischemic risk